17th Feb 2025 17:54
hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Signs GBP2 million contract with a new biopharmaceutical client to complete the final stage of its pilot human metapneumovirus characterisation study ahead of future hMPV human challenge trials. The final phase of the study is expected to commence in the first half of 2025, with the revenue being recognised in 2025. hVIVO expects to be in a position to commence hMPV HCTs from the second half of the year, subject to the successful completion of this study and receipt of the necessary regulatory approvals. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Severe cases can result in bronchiolitis, bronchitis and pneumonia. Despite this, hVIVO points out there are currently no vaccines or antivirals approved to treat hMPV. Read More
